Reprogramming the tumor microbiome: Opportunities for cancer prevention, diagnosis, and precision therapy
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-11 · 1881 (6) · 189748
DOI: 10.1016/j.bbcan.2026.189748 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-11. Verfasst von Gamal M El-Sherbiny. Beteiligte Einrichtung: Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo 11884, Egypt. Electronic address: gamalelsherbiny1970@azhar.edu.eg. Die Arbeit nennt 224 Literaturangaben.
Abstract (Originalsprache)
Microbiota-cancer interactions operate across distinct anatomical compartments, including the gut microbiota, the distal gut-tumor axis, and intratumoral microbiota residing within tumor tissues. These microbial communities and their metabolites can influence carcinogenesis, tumor progression, immune surveillance, and therapeutic responses through inflammation, genotoxicity, metabolic remodeling, epithelial and tumor-barrier dysfunction, and immune regulation. However, the magnitude and direction of these effects are highly context dependent, varying with cancer type, tumor site, microbial composition, host factors, treatment exposure, and methodological approaches. Importantly, associations between microbial signatures and clinical outcomes do not necessarily establish causality, and findings from gut microbiome studies should not be extrapolated directly to local intratumoral communities. This review critically synthesizes current evidence linking gut and intratumoral microbiota to tumor biology and treatment response, distinguishing compartment-specific mechanisms and evaluating the strength and limitations of available evidence. We examine how microbial metabolites, microbe-host interactions, and microbiota-driven immune and metabolic pathways shape the tumor microenvironment and may modify responses to immunotherapy, chemotherapy, radiotherapy, and targeted therapies. We further assess multi-omics and spatial approaches for resolving microbial heterogeneity and identifying clinically relevant biomarkers, alongside emerging microbiome-directed interventions, including probiotics, fecal microbiota transplantation, engineered microorganisms, and nanotechnology-based strategies. Particular emphasis is placed on discrepancies between preclinical and clinical findings, causal inference, reproducibility, interindividual variability, contamination and sampling challenges, and the barriers to clinical translation. Collectively, the evidence supports a context-specific role for microbiota in cancer biology while underscoring the need for standardized methodologies, longitudinal and mechanistic studies, and well-controlled clinical trials before microbiome-based strategies can be reliably incorporated into precision oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo 11884, Egypt. Electronic address: gamalelsherbiny1970@azhar.edu.eg.
Zitieren
APA
El-Sherbiny, G. M. (2026). Reprogramming the tumor microbiome: Opportunities for cancer prevention, diagnosis, and precision therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(6), 189748. https://doi.org/10.1016/j.bbcan.2026.189748
Vancouver
El-Sherbiny GM. Reprogramming the tumor microbiome: Opportunities for cancer prevention, diagnosis, and precision therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(6):189748. doi:10.1016/j.bbcan.2026.189748
BibTeX
@article{ElSherbiny2026,
author = {El-Sherbiny, Gamal M},
title = {Reprogramming the tumor microbiome: Opportunities for cancer prevention, diagnosis, and precision therapy},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {6},
pages = {189748},
doi = {10.1016/j.bbcan.2026.189748}
}
EUVIMED